This book covers wide areas of animal and human psychopharmacology with clinical utility in the treatment of psychiatric and neurological (e.g Alzheimer's disease) disorders. The main theme is to develop a new paradigm for drug discovery that questions the claim that animal models or assays fail adequately to predict Phase 3 clinical trials. A new paradigm is advocated that stresses the importance of intermediate staging points between these extremes that depend on suitable translation of findings from animal studies to Phase 1 or Phase 2 studies utilising experimental medicine.
Rezensionen / Stimmen
"This book examines the 'translational gap' between animal models of neuropsychiatric disease and human studies. . The intended audience is scientists working on problems related to neuropsychopharmacology. . This is an important addition to the literature on translational neurosciences. It is an important contribution to understanding both the current state of this field and its possible future directions." (Eric Gausche, Doody's Book Reviews, November, 2016)
Reihe
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Illustrationen
32
92 farbige Abbildungen, 32 s/w Abbildungen
XII, 498 p. 124 illus., 92 illus. in color.
Dateigröße
ISBN-13
978-3-319-33913-9 (9783319339139)
DOI
10.1007/978-3-319-33913-9
Schweitzer Klassifikation
